Neuroimmune pharmacological control of EAE

Journal of Neuroimmune Pharmacology

Volumn 5, Issue 2, 2010, Pages 165-167

  Pahan, Kalipada ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(1 BUTYLAMINO 3 METHYLBUTYL)(1 PYRROLIDINYL) KETONE; CURDLAN; CYCLOPHOSPHAMIDE; ENCEPHALITOGENIC PROTEIN; GAMMA INTERFERON; GLATIRAMER; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERFERON; MITOXANTRONE; MYELIN; NATALIZUMAB; RECOMBINANT PROTEIN;

ADAPTIVE IMMUNITY; ALLERGIC ENCEPHALOMYELITIS; BLOOD BRAIN BARRIER; CLONAL VARIATION; DEMYELINATING DISEASE; EXPERIMENTAL ANIMAL; HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; MULTIPLE SCLEROSIS; NEUROIMMUNOLOGY; NONHUMAN; NOTE; OLIGODENDROGLIA; PRIORITY JOURNAL; RABBIT; SPINAL CORD;

ANIMALS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GENES, T-CELL RECEPTOR; HUMANS; INTERLEUKIN-17; MACROPHAGES; MULTIPLE SCLEROSIS; T-LYMPHOCYTES; TH1 CELLS; TH2 CELLS;

EID: 77954563637     PISSN: 15571890     EISSN: 15571904     Source Type: Journal    
DOI: 10.1007/s11481-010-9219-6     Document Type: Note

References (11)

1. El-Behi M, Rostami A, Ciric B (2010) Current views on the roles of Th1 and Th17 cells in experimental autoimmune encephalomyelitis. J Neuroimmune Pharmacol. doi:10.1007/s11481-009-9188-9
2. Kap YS, Laman JD, 't Hart BA (2010) Experimental autoimmune encephalomyelitis in the common marmoset, a bridge between rodent EAE and multiple sclerosis for immunotherapy development. J Neuroimmune Pharmacol. doi:10.1007/s11481-009- 9178-y
3. Lee J, Sandor M, Heninger E, Fabry Z (2010) Mycobacteria-induced suppression of autoimmunity in the central nervous system. J Neuroimmune Pharmacol. doi:10.1007/s11481-010-9199-6
4. Li H, Rostami A (2010) IL-9: basic biology, signaling pathways in CD4+ T cells and implications for autoimmunity. J Neuroimmune Pharmacol. doi:10.1007/s11481-009-9186-y
5. Libbey JE, Tsunoda I, Fujinami RS (2010) Studies in the modulation of experimental autoimmune encephalomyelitis. J Neuroimmune Pharmacol. doi:10.1007/s11481-010-9215-x
6. Nath N, Morinaga O, Singh I (2010) S-nitrosoglutathione a physiologic nitric oxide carrier attenuates experimental autoimmune encephalomyelitis. J Neuroimmune Pharmacol. doi:10.1007/s11481-009-9187-x
7. Ren Z, Wang Y, Tao D, Liebenson D, Liggett T, Goswami R, Stefoski D, Balabanov R (2010) Central nervous system expression of interferon regulatory factor 1 regulates experimental autoimmune encephalomyelitis. J Neuroimmune Pharmacol. doi:10.1007/ s11481-010-9193-z
8. Rivers TM, Sprunt DH, Berry GP (1933) Observations on attempts to produce acute disseminated encephalomyelitis in monkeys. J Expt Med 58:39-53
9. Sabatino JJ Jr, Rosenthal KM, Evavold BD (2010) Manipulating antigenic ligand strength to selectively target myelin-reactive CD4+ T cells in EAE. J Neuroimmune Pharmacol. doi:10.1007/ s11481-009-9181-9183
10. Simonini MV, Polak PE, Sharp A, McGuire S, Galea E, Feinstein DL (2010) Increasing CNS noradrenaline reduces EAE severity. J Neuroimmune Pharmacol. doi:10.1007/s11481-009-9182-2
11. Sinha S, Subramanian S, Emerson-Webber A, Lindner M, Burrows GG, Grafe M, Linington C, Vandenbark AA, Bernard CC, Offner H (2010) Recombinant TCR ligand reverses clinical signs and CNS damage of EAE induced by recombinant human MOG. J Neuroimmune Pharmacol. doi:10.1007/s11481-009-9175-1